Related Experiment Video
Updated: Feb 5, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer
Chang-Ching Lin1, Miao-Chia Lo1, Rebecca Moody2
1Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.
Abstract:
Triple-negative breast cancer (TNBC) is the most difficult subtype of breast cancer to treat due to a paucity of effective targeted therapies. Many studies have reported that breast cancer stem cells (BCSCs) are enriched in TNBC and are responsible for chemoresistance and metastasis. In this study, we identify LRP8 as a novel positive regulator of BCSCs in TNBC. LRP8 is highly expressed in TNBC compared to other breast cancer subtypes and its genomic locus is amplified in 24% of TNBC tumors. Knockdown of LRP8 in TNBC cell lines inhibits Wnt/β-catenin signaling, decreases BCSCs, and suppresses tumorigenic potential in xenograft models. LRP8 knockdown also induces a more differentiated, luminal-epithelial phenotype and thus sensitizes the TNBC cells to chemotherapy. Together, our study highlights LRP8 as a novel therapeutic target for TNBC as inhibition of LRP8 can attenuate Wnt/β-catenin signaling to suppress BCSCs.
Insights
Triple-negative breast cancer (TNBC) is hard to treat. This study finds LRP8 promotes cancer stem cells in TNBC, suggesting LRP8 as a new therapeutic target to improve treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
Background:
- Triple-negative breast cancer (TNBC) presents significant therapeutic challenges due to limited targeted treatments.
- Breast cancer stem cells (BCSCs) are implicated in TNBC's chemoresistance and metastatic potential.
Purpose of the Study:
- To identify novel regulators of BCSCs in TNBC.
- To investigate the role of LRP8 in TNBC progression and therapeutic sensitivity.
Main Methods:
- Expression analysis of LRP8 in breast cancer subtypes.
- LRP8 knockdown in TNBC cell lines.
- Assessment of Wnt/β-catenin signaling pathway activity.
- Evaluation of BCSC populations and tumorigenic potential in xenograft models.
- Analysis of cellular phenotype and chemosensitivity post-LRP8 knockdown.
Main Results:
- LRP8 is highly expressed and its locus amplified in TNBC.
- LRP8 knockdown inhibits Wnt/β-catenin signaling, reduces BCSCs, and suppresses tumor growth.
- LRP8 inhibition promotes a differentiated phenotype and enhances chemotherapy sensitivity in TNBC cells.
Conclusions:
- LRP8 acts as a positive regulator of BCSCs in TNBC.
- Targeting LRP8 represents a promising therapeutic strategy for TNBC by suppressing BCSCs and overcoming chemoresistance.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Distinctive Features of Adult Stem Cells vs Cancer Stem Cells
Adult stem cells
Adult stem cells are tissue-specific; hence, they divide to develop the tissue from which they originate. One type of adult stem cell is the epithelial stem cell, which gives rise to the keratinocytes in the multiple layers of epithelial cells in the epidermis of the skin. Adult bone marrow has three distinct types of stem cells:...
Cancer
Cancer Cell Migration through Invadopodia
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...

